Effectiveness of HeberFERON® in the treatment of basal cell carcinoma of the back of the nose
Abstract
Introduction: basal cell carcinoma is the most common cause of neoplasms, without distinction between racial groups, ethnic groups or ages.
Objective: to evaluate the effectiveness of HeberFERON® for the treatment of basal cell carcinoma of the back of the nose.
Methods: a pre-experimental study of the before and after type was carried out at the Ciego de Ávila Provincial General Teaching Hospital, in the period July 2017 to April 2019. It worked with the 32 adults who met the inclusion criteria. Two treatment schemes were applied with different doses and ways of administration. Chi-square, Mann-Whitney's U, and Cochran's Q tests were used. Ethical principles were met.
Results: the general mean age was 70 years (DT =16,0) with a predominance of males (59,40 %), urban origin (56,25 %), skin phenotype II (53,10 %), the clinical form and nodular dermatological pattern, and erythema as an adverse event. The complete clinical response was observed in all histological forms and patterns, with a predominance of the nodular. The frequency of applications was associated with the complete clinical response. Telangiectasia was the most commonly observed dermoscopic finding (100 %). Only one patient presented partial persistence of the injury to the second year, unrelated to the number or type of injury.
Conclusions: the therapeutic effectiveness of HeberFERON® was demonstrated in patients with basal cell carcinoma of the back of the nose. In all clinical forms and histological patterns studied, the complete clinical response, safety and tolerability were goodDownloads
Published
How to Cite
Issue
Section
License
MediCiego does not apply publication charges. The journal is available in open access without restrictions, in compliance with the international policy on open access to information for the exchange of global knowledge.
The authors will retain their copyright and guarantee the journal the right of first publication of their work. MediCiego is licensed under the Creative Commons Attribution-NonCommercial 4.0 International license (CC BY-NC 4.0) https://creativecommons.org/licenses/by-nc/4.0/deed.es_ES), so it is allowed to copy, reproduce, distribute, publicly communicate the work and generate derivative works, as long as the original author is cited and acknowledged. However, it is not allowed to use the original work for commercial or lucrative purposes.
Authors must sign a copyright agreement through an affidavit of authorship and originality, before publishing.
The authors authorize the publication of their writings; they retain the copyright, and assign to the journal all the rights protected by the Copyright Law that governs Cuba, and implies the edition to disseminate the work.
Likewise, they may establish additional agreements for the non-exclusive distribution of the version of the work published in the journal (for example, placing it in an institutional repository or publishing it in a book), with the recognition of having been first published in this journal.
Declaration of authorship: download here the Affidavit
